Reports
Reports
Sale
The global hospital acquired disease testing market attained a value of USD 1609.43 million in 2023. The market is further anticipated to reach USD 6312.63 million by 2032 while registering a CAGR of 16.4% over the forecast period of 2024-2032.
On the basis of the indication, the urinary tract infection segment is estimated to be the largest indication segment. The segment growth is primarily attributed to the rising incidences of immune suppression accompanied by urologic abnormality due to the consumption of unhealthy food, alcohol, and smoking.
Regionally, North America is anticipated to dominate the market in 2020, owing to the increasing reimbursement policies and favourable government initiatives towards hospital acquired (nosocomial) infections.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
A hospital acquired infection (HAI) or diseases or nosocomial infection is an infection which is acquired from the hospital or the clinical surrounding including nursing homes, and rehabilitation centres, among others. The incubation period of the nosocomial infection generally varies between 48 hours to 4 days. The prime reason behind the cause of HAI is the lack of proper hygiene in the hospital or clinical environment by the internal staff. Also, other factors that can be attributed to the growth of HAI include below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the commonly occurring nosocomial infections include pneumonia, urinary tract infections (UTI), and primary bloodstream infections.
On the basis of indication, the market is segmented into:
The EMR report looks into the regional markets of hospital acquired disease testing like Europe, the Asia Pacific, North America, Latin America, and the Middle East and Africa.
With the increasing global population, rapid urbanisation, and modernisation of healthcare infrastructure, there has been a significant increase in the number of health care facilities. This has led to the rising incidence of HAIs, which, in turn, is propelling the demand for hospital acquired disease tests. The rising adoption of advanced technologies for preventing, diagnosing, and monitoring HAIs, such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridisation, is further expected to augment the market growth.
Moreover, the growing awareness of HAIs among patients and stringent government regulations to penalize hospitals with a high incidence of HAIs are some of the other factors that are strengthening the growth of the market. Increasing research and development activities for developing new techniques, coupled with various mergers and acquisitions and strategic partnerships by various manufacturers, are expected to create potential revenue opportunities for players operating in the market over the forecast period.
The report presents a detailed analysis of the following key players in the global hospital acquired disease testing market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter's Five Forces model.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Indication |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Hospital Acquired Disease Testing Market Analysis
8.1 Key Industry Highlights
8.2 Global Hospital Acquired Disease Testing Historical Market (2018-2023)
8.3 Global Hospital Acquired Disease Testing Market Forecast (2024-2032)
8.4 Global Hospital Acquired Disease Testing Market by Indication
8.4.1 UTI (Urinary Tract Infection)
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2023)
8.4.1.3 Forecast Trend (2024-2032)
8.4.2 SSI (Surgical Site Infection)
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2023)
8.4.2.3 Forecast Trend (2024-2032)
8.4.3 Pneumonia
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2023)
8.4.3.3 Forecast Trend (2024-2032)
8.4.4 Bloodstream Infections
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2023)
8.4.4.3 Forecast Trend (2024-2032)
8.4.5 MRSA (Methicillin-Resistant Staphylococcus Aureus)
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2018-2023)
8.4.5.3 Forecast Trend (2024-2032)
8.4.6 Others
8.5 Global Hospital Acquired Disease Testing Market by Region
8.5.1 North America
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2023)
8.5.1.3 Forecast Trend (2024-2032)
8.5.2 Europe
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2023)
8.5.2.3 Forecast Trend (2024-2032)
8.5.3 Asia Pacific
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2023)
8.5.3.3 Forecast Trend (2024-2032)
8.5.4 Latin America
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2023)
8.5.4.3 Forecast Trend (2024-2032)
8.5.5 Middle East and Africa
8.5.5.1 Market Share
8.5.5.2 Historical Trend (2018-2023)
8.5.5.3 Forecast Trend (2024-2032)
9 North America Hospital Acquired Disease Testing Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2023)
9.1.3 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2023)
9.2.3 Forecast Trend (2024-2032)
10 Europe Hospital Acquired Disease Testing Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2023)
10.1.3 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2023)
10.2.3 Forecast Trend (2024-2032)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2023)
10.3.3 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2023)
10.4.3 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Hospital Acquired Disease Testing Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2023)
11.1.3 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2023)
11.2.3 Forecast Trend (2024-2032)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2023)
11.3.3 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2023)
11.4.3 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2023)
11.5.3 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Hospital Acquired Disease Testing Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2023)
12.1.3 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2023)
12.2.3 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2023)
12.3.3 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Hospital Acquired Disease Testing Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2023)
13.1.3 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2023)
13.2.3 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2023)
13.3.3 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2023)
13.4.3 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Value Chain Analysis
16 Competitive Landscape
16.1 Market Structure
16.2 Company Profiles
16.2.1 Abbott Laboratories
16.2.1.1 Company Overview
16.2.1.2 Product Portfolio
16.2.1.3 Demographic Reach and Achievements
16.2.1.4 Certifications
16.2.2 Becton, Dickinson and Company
16.2.2.1 Company Overview
16.2.2.2 Product Portfolio
16.2.2.3 Demographic Reach and Achievements
16.2.2.4 Certifications
16.2.3 F. Hoffmann-La Roche Ltd.
16.2.3.1 Company Overview
16.2.3.2 Product Portfolio
16.2.3.3 Demographic Reach and Achievements
16.2.3.4 Certifications
16.2.4 Hologic, Inc.
16.2.4.1 Company Overview
16.2.4.2 Product Portfolio
16.2.4.3 Demographic Reach and Achievements
16.2.4.4 Certifications
16.2.5 Siemens Healthcare GmbH
16.2.5.1 Company Overview
16.2.5.2 Product Portfolio
16.2.5.3 Demographic Reach and Achievements
16.2.5.4 Certifications
16.2.6 Others
17 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Hospital Acquired Disease Testing Market: Key Industry Highlights, 2018 and 2032
2. Global Hospital Acquired Disease Testing Historical Market: Breakup by Indication (USD Million), 2018-2023
3. Global Hospital Acquired Disease Testing Market Forecast: Breakup by Indication (USD Million), 2024-2032
4. Global Hospital Acquired Disease Testing Historical Market: Breakup by Region (USD Million), 2018-2023
5. Global Hospital Acquired Disease Testing Market Forecast: Breakup by Region (USD Million), 2024-2032
6. North America Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2018-2023
7. North America Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
8. Europe Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2018-2023
9. Europe Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
10. Asia Pacific Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2018-2023
11. Asia Pacific Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Latin America Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2018-2023
13. Latin America Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Middle East and Africa Hospital Acquired Disease Testing Historical Market: Breakup by Country (USD Million), 2018-2023
15. Middle East and Africa Hospital Acquired Disease Testing Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Global Hospital Acquired Disease Testing Market Structure
In 2023, the global hospital acquired disease testing market attained a value of nearly USD 1609.43 million.
In the forecast period of 2024-2032, the market is expected to grow at a CAGR of 16.4%.
By 2032, the market is expected to attain a value of USD 6312.63 million.
The major drivers of the market include the increasing incidences of immune suppression, the introduction of favourable government initiatives aimed at increasing reimbursement policies towards hospital acquired diseases, and growing global population.
The modernisation of healthcare, the rising adoption of advanced technologies for preventing, diagnosing, and treating hospital acquired diseases, growing awareness regarding hospital acquired diseases among patients, and increasing research activities to develop advanced diagnostic technologies are the key trends guiding the market.
The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The significant indication segments considered in the market report include UTI (urinary tract infection), SSI (surgical site infection), pneumonia, bloodstream infections, and MRSA (methicillin-resistant staphylococcus aureus), among others.
The major players in the market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., and Siemens Healthcare GmbH, among others.
The global hospital acquired disease testing market attained a value of USD 1609.43 million in 2023, driven by the modernisation of the healthcare infrastructure. Aided by technological advancements, the market is expected to witness a further growth in the forecast period of 2024-2032, growing at a CAGR of 16.4%. The market is projected to reach USD 6312.63 million by 2032.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on indication, the market can be segmented into UTI (urinary tract infection), SSI (surgical site infection), pneumonia, bloodstream infections, and MRSA (methicillin-resistant staphylococcus aureus), among others, with UTI (urinary tract infection) accounting for the largest market share. The major regional markets for hospital acquired disease are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share of the market. The key players in the above market include Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Hologic, Inc., and Siemens Healthcare GmbH, among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition. Global Hospital Acquired Disease Testing Market
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.